专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2008020967A2 CATHETER AND ARRAY FOR ANTICANCER THERAPY 审中-公开
标题翻译：导管和阵列治疗
公开(公告)号：WO2008020967A2
公开(公告)日：2008-02-21
申请号：PCT/US2007/016701
申请日：2007-07-25
申请人： PEAK BIOSCIENCES, INC. , MATSUURA, James, E. , WARREN, Stephen, L.
发明人： MATSUURA, James, E. , WARREN, Stephen, L.
IPC分类号： A61M25/01
CPC分类号： A61M25/0662 , A61M25/0021 , A61M25/0032 , A61M25/0068 , A61M25/007 , A61M25/0074 , A61M25/008 , A61M25/0084 , A61M2025/0036 , A61M2025/0081 , A61M2025/0175
摘要： A catheter array system adapted for implanting a plurality of catheters within the tissue of a patient in a spatially defined array, comprising a plurality of catheters, a catheter guide template adapted to guide the implantation of catheters, and a liquid supply system including a pressurizer and a manifold, is provided. A method of treatment of a malcondition in a patient comprises implantation of a spatially definted array of catheters using the system is also provided. The bioactive agent can be a radiotherapeutic agent, a chemotherapeutic agent, a protein, an antibody, an oligonucleotide-based therapeutic agent such as siRNA, or a combination of agents. A preferred radiotherapeutic agent is 123 I- or 125 I-IUDR, for example in the treatment of locally advanced tumors, such as glioblastoma multiforme.
摘要翻译：一种导管阵列系统，其适于在空间限定的阵列中将多个导管植入患者的组织内，包括多个导管，适于引导导管植入的导管引导模板，以及包括加压器和提供了一个歧管。还提供了一种治疗患者病情的方法，包括使用该系统植入空间有限的导管阵列。生物活性剂可以是放射治疗剂，化学治疗剂，蛋白质，抗体，基于寡核苷酸的治疗剂如siRNA或药剂的组合。优选的放射治疗剂是123 I型或125 I-IUDR，例如用于局部晚期肿瘤的治疗，例如多形性成胶质细胞瘤。

2. 发明申请

WO2008115511A1 METHOD FOR THERAPEUTIC ADMINISTRATION OF RADIONUCLEOSIDES 审中-公开
标题翻译：放射性核素治疗药物治疗方法
公开(公告)号：WO2008115511A1
公开(公告)日：2008-09-25
申请号：PCT/US2008/003582
申请日：2008-03-19
申请人： PEAK BIOSCIENCES, INC. , DALKE, William, D. , GERBER, Michael, J. , LILLEHEI, Kevin, O. , MATSUURA, James, E. , WARREN, Stephen, L.
发明人： DALKE, William, D. , GERBER, Michael, J. , LILLEHEI, Kevin, O. , MATSUURA, James, E. , WARREN, Stephen, L.
IPC分类号： A61K51/00
CPC分类号： A61K51/0491 , Y10T137/0402
摘要： Methods are provided for the local radiotherapy of cancers such as locally invasive, advanced stage solid tumors, and normal tissues penetrated by processes of cancerous tissue, through administration of Auger-electron emitting radionucleoside analogs using high-flow microinfusion techniques ("convection-enhanced delivery"). Direct infusion under pressure, at flow rates in excess of at least about 0.5 microliters/min of the radionucleosides provides for their mass transport through tissue to a much higher degree than could be achieved by passive, unpressurized diffusion. The unique properties of these radionucleoside analogs that provide for surprisingly effacacious delivery by high-flow microinfusion include rapid clearance from tissues following local injection without the benefit of sustained high-flow microinfusion, rapid and complete clearance via the blood stream, poor permeation of barriers such as the blood-brain barrier, and a highly potent, non-selective, but very short range killing effect on cells that are undergoing DNA replication that incorporate radionucleosides into their chromosomes.
摘要翻译：通过使用高流量微灌注技术（“对流增强递送”）施用俄歇电子发射放射性核苷类似物，提供了局部放射治疗癌症的方法，例如局部浸润性，晚期实体瘤和由癌组织进程穿透的正常组织 “）。在压力下直接输注超过至少约0.5微升/分钟的放射性核苷的流速提供了它们通过组织传播的程度比通过被动的，未加压的扩散可以达到的程度高得多。这些放射性核苷类似物的独特性质通过高流量微灌注提供令人惊讶的高效递送包括局部注射后从组织中快速清除，而不受持续的高流量微灌注的影响，通过血流快速和完全清除，障碍物渗透差作为血脑屏障，以及对正在经历DNA复制的细胞的非常有效，非选择性但非常短程的杀伤作用，其将放射性核苷掺入染色体。

3. 发明申请

WO2006084141A2 SUSPENSION FORMULATION OF INTERFERON 审中-公开
标题翻译：干扰素的悬浮剂
公开(公告)号：WO2006084141A2
公开(公告)日：2006-08-10
申请号：PCT/US2006/003861
申请日：2006-02-02
申请人： ALZA CORPORATION , AYER, Rupal A. , DENNIS, Paula , DESJARDIN, Michael A. , LAM, Stanley , LIU, Kui , MATSUURA, James E. , NARAYANAN, Latha , ROHLOFF, Catherine , ZAMORA, Pauline C.
发明人： AYER, Rupal A. , DENNIS, Paula , DESJARDIN, Michael A. , LAM, Stanley , LIU, Kui , MATSUURA, James E. , NARAYANAN, Latha , ROHLOFF, Catherine , ZAMORA, Pauline C.
IPC分类号： A61K38/21 , A61P31/12 , A61K9/10 , A61K47/14 , A61K47/32 , A61K47/26 , A61K47/18
CPC分类号： A61K38/21 , A61F2250/0068 , A61K9/0004 , A61K9/0019 , A61K9/0024 , A61K9/10 , A61K9/1617 , A61K9/1623 , A61K9/1694 , A61K9/19
摘要： A suspension formulation of interferon includes a non-aqueous, single-phase vehicle including at least one polymer and at least one solvent, the vehicle exhibiting viscous fluid characteristics, and an interferon contained in a particle formulation dispersed in the vehicle. The particle formulation includes a stabilizing component comprising one or more stabilizers selected from the group consisting of carbohydrates, antioxidants, and amino acids. The suspension formulation is characterized in that less than 10% of the interferon degrades over 3 months under an accelerated storage condition.
摘要翻译：干扰素的混悬液制剂包括非水性单相载体，其包含至少一种聚合物和至少一种溶剂，所述载体表现出粘性流体特性，且包含在分散的颗粒制剂中的干扰素在车内。颗粒制剂包括稳定化组分，其包含一种或多种选自碳水化合物，抗氧化剂和氨基酸的稳定剂。该悬浮液制剂的特征在于，在加速储存条件下，少于10％的干扰素在3个月内降解。

4. 发明申请

WO2008140808A1 METHODS FOR ADMINISTRATION OF RADIOTHERAPEUTIC AGENTS 审中-公开
标题翻译：放射治疗药物的管理方法
公开(公告)号：WO2008140808A1
公开(公告)日：2008-11-20
申请号：PCT/US2008/006040
申请日：2008-05-09
申请人： PEAK BIOSCIENCES, INC. , GERBER, Michael, J. , WARREN, Stephen, L. , MATSUURA, James, E.
发明人： GERBER, Michael, J. , WARREN, Stephen, L. , MATSUURA, James, E.
IPC分类号： A01N43/42
CPC分类号： A61K31/00 , A61K38/1703 , A61K38/18 , A61K38/1866 , A61K38/195 , A61K38/20 , A61K38/22 , A61K45/06 , A61K48/00 , A61K51/0491 , A61K2300/00
摘要： A method is provided for treatment of disorders involving hyperproliferative cells, such as malignancies, advanced stage solid tumors like glioblastoma multiforme, and non-malignant hyperproliferative pathological conditions such as adult macular degeneration. A short range, unselective cell killing radiotherapeutic substance is administered, optionally in a spatially defined volume of tissue, optionally in combination with a mitogenic agent that stimulates or induces DNA biosynthesis. In this way, the percentage of hyperproliferative that are susceptible to killing by the radiotherapeutic agent is increased. Cancer stem cells can be induced to enter S phase with the mitogenic agent, then killed with the radiotherapeutic agent. Thus, not only does the combination effectively kill the transit amplifying cell population, the most rapidly replicating type of cell in a tumor, but it also effectively kills the tumor stem cells, which give rise to the transit amplifying cells, for a longer lasting anticancer effect.
摘要翻译：提供了用于治疗涉及过度增殖细胞例如恶性肿瘤，晚期实体瘤如多形性成胶质细胞瘤的病症和非恶性过度增殖病理状况如成人黄斑变性的病症的方法。任选地在空间上限定的组织体内施用短程，非选择性细胞杀伤放射治疗物质，任选与刺激或诱导DNA生物合成的促有丝分裂剂组合。以这种方式，放射治疗剂易于杀死的过度增殖的百分比增加。可以诱导癌干细胞与促有丝分裂剂进入S期，然后用放射治疗剂杀死。因此，不仅组合有效地杀死了肿瘤中最快速复制型细胞的转运扩增细胞群，而且还有效地杀死了产生转运扩增细胞的肿瘤干细胞，以达到更持久的抗癌作用影响。

5. 发明申请

WO2007064845A1 SUSTAINED RELEASE BUTORPHANOL DRUG DELIVERY COMPOSITIONS FOR ANALGESIA 审中-公开
标题翻译：持续释放用于治疗的非酒精性药物组合物
公开(公告)号：WO2007064845A1
公开(公告)日：2007-06-07
申请号：PCT/US2006/045932
申请日：2006-11-29
申请人： PR PHARMACEUTICALS, INC. , MATSUURA, James, E. , ZEIGERSON, Ehud
发明人： MATSUURA, James, E. , ZEIGERSON, Ehud
IPC分类号： A61F13/00
CPC分类号： A61K9/0024 , A61K9/0019 , A61K9/14 , A61K31/485 , A61K47/10
摘要： The invention is directed to a composition comprising a water-insoluble form of butorphanol for non-vascular administration whereby an analgesic effect from the composition lasts at least one day. The invention is further directed to methods of making a water insoluble butorphanol composition and producing butorphanol particles with a defined particle size.
摘要翻译：本发明涉及包含用于非血管给药的水不溶性形式的布托啡醇的组合物，由此组合物的镇痛作用持续至少一天。本发明进一步涉及制备水不溶性布可芬组合物并制备具有规定粒度的布可诺啡颗粒的方法。

6. 发明申请

WO2006084139A3 AN IMPLANTABLE INTERFERON-CONTAINING DEVICE 审中-公开
标题翻译：可植入的含有干扰物的装置
公开(公告)号：WO2006084139A3
公开(公告)日：2006-10-19
申请号：PCT/US2006003857
申请日：2006-02-03
申请人： ALZA CORP , DENNIS PAULA , DESJARDIN MICHAEL A , LAM STANLEY , LIU KUI , MATSUURA JAMES E , NARAYANAN LATHA , ROHLOFF CATHERINE , ZAMORA PAULINE C
发明人： DENNIS PAULA , DESJARDIN MICHAEL A , LAM STANLEY , LIU KUI , MATSUURA JAMES E , NARAYANAN LATHA , ROHLOFF CATHERINE , ZAMORA PAULINE C
IPC分类号： A61K38/21 , A61K9/00
CPC分类号： A61K38/21 , A61F2250/0068 , A61K9/0004 , A61K9/0019 , A61K9/0024 , A61K9/10 , A61K9/1617 , A61K9/1623 , A61K9/1694 , A61K9/19
摘要： An implantable device includes a reservoir containing a suspension of an interferon in an amount sufficient to provide continuous delivery of the interferon at a therapeutically effective rate of 1 ng/day to 600 µg/day to maintain and achieve therapeutic blood or plasma levels of the interferon throughout a substantial period of the administration period.
摘要翻译：可植入装置包括含有干扰素悬浮液的储存器，该悬浮液的量足以以1ng /天至600μg/天的治疗有效速率提供干扰素的连续递送，以维持和实现干扰素的治疗性血液或血浆水平在行政期间的很长一段时期。

7. 发明申请

WO2008115566A3 GUIDANCE AND IMPLANTATION OF CATHETERS 审中-公开
标题翻译：导管的指导和植入
公开(公告)号：WO2008115566A3
公开(公告)日：2009-12-23
申请号：PCT/US2008003711
申请日：2008-03-20
申请人： PEAK BIOSCIENCES INC , DALKE WILLIAM D , GERBER MICHAEL J , JELLISON THOMAS A , LILLEHEI KEVIN O , MATSUURA JAMES E , WARREN STEPHEN L
发明人： DALKE WILLIAM D , GERBER MICHAEL J , JELLISON THOMAS A , LILLEHEI KEVIN O , MATSUURA JAMES E , WARREN STEPHEN L
IPC分类号： A61M25/18
CPC分类号： A61K51/0491 , Y10T137/0402
摘要： A catheter system adapted for navigating, guiding and implanting a catheter or a plurality of catheters in a spatially-defined implantation within the tissue of a patient is provided. The system can include a tissue navigation system and a probe to inform the navigation system to guide emplacement of the catheters within a target tissue. The probe can provide images, such as fiberoptic visual images, or ultrasound images, or can provide radiolocation data, to guide the catheter emplacement. The catheters supply a pressurized liquid including a bioactive agent, such as can be used in the treatment of cancer, for example 123I- or 125I-IUDR. The system and methods provided can be used in the treatment of locally advanced tumors, such as cancers of the brain, head or neck, esophagus, prostate, ovary, liver, pancreas, bladder or rectum.
摘要翻译：提供了一种导管系统，其适于在病人组织内的空间限定的植入物中导航，引导和植入导管或多个导管。该系统可以包括组织导航系统和探针，以通知导航系统来引导导管在目标组织内的位置。探针可以提供诸如光学视觉图像或超声图像的图像，或者可以提供无线电定位数据来引导导管放置。导管提供包括生物活性剂的加压液体，例如可用于治疗癌症，例如123I-或125I-IUDR。提供的系统和方法可用于局部晚期肿瘤的治疗，如脑，头颈部，食管，前列腺，卵巢，肝，胰腺，膀胱或直肠癌。

8. 发明申请

WO2008020967A3 CATHETER AND ARRAY FOR ANTICANCER THERAPY 审中-公开
标题翻译：用于抗癫痫治疗的导管和阵列
公开(公告)号：WO2008020967A3
公开(公告)日：2008-11-20
申请号：PCT/US2007016701
申请日：2007-07-25
申请人： PEAK BIOSCIENCES INC , MATSUURA JAMES E , WARREN STEPHEN L
发明人： MATSUURA JAMES E , WARREN STEPHEN L
IPC分类号： A61M5/00
CPC分类号： A61M25/0662 , A61M25/0021 , A61M25/0032 , A61M25/0068 , A61M25/007 , A61M25/0074 , A61M25/008 , A61M25/0084 , A61M2025/0036 , A61M2025/0081 , A61M2025/0175
摘要： A catheter array system adapted for implanting a plurality of catheters within the tissue of a patient in a spatially defined array, comprising a plurality of catheters, a catheter guide template adapted to guide the implantation of catheters, and a liquid supply system including a pressurizer and a manifold, is provided. A method of treatment of a malcondition in a patient comprises implantation of a spatially definted array of catheters using the system is also provided. The bioactive agent can be a radiotherapeutic agent, a chemotherapeutic agent, a protein, an antibody, an oligonucleotide-based therapeutic agent such as siRNA, or a combination of agents. A preferred radiotherapeutic agent is 123 I- or 125 I-IUDR, for example in the treatment of locally advanced tumors, such as glioblastoma multiforme.
摘要翻译：适于以空间限定阵列将多个导管植入患者组织内的导管阵列系统包括多个导管，适于引导导管植入的导管引导模板以及包括加压器的液体供应系统和提供歧管。还提供了一种治疗患者恶化的方法，该方法包括使用该系统植入空间限定的导管阵列。生物活性剂可以是放射治疗剂，化学治疗剂，蛋白质，抗体，基于寡核苷酸的治疗剂例如siRNA，或者药剂的组合。优选的放射治疗剂是例如用于局部晚期肿瘤如多形性成胶质细胞瘤的治疗中的I-123或I-IUDR。

9. 发明申请

WO2008115566A2 GUIDANCE AND IMPLANTATION OF CATHETERS 审中-公开
标题翻译：导管的指导和植入
公开(公告)号：WO2008115566A2
公开(公告)日：2008-09-25
申请号：PCT/US2008/003711
申请日：2008-03-20
申请人： PEAK BIOSCIENCES, INC. , DALKE, William, D. , GERBER, Michael, J. , JELLISON, Thomas, A. , LILLEHEI, Kevin, O. , MATSUURA, James, E. , WARREN, Stephen, L.
发明人： DALKE, William, D. , GERBER, Michael, J. , JELLISON, Thomas, A. , LILLEHEI, Kevin, O. , MATSUURA, James, E. , WARREN, Stephen, L.
IPC分类号： A61M25/09
CPC分类号： A61K51/0491 , Y10T137/0402
摘要： A catheter system adapted for navigating, guiding and implanting a catheter or a plurality of catheters in a spatially-defined implantation within the tissue of a patient is provided. The system can include a tissue navigation system and a probe to inform the navigation system to guide emplacement of the catheters within a target tissue. The probe can provide images, such as fiberoptic visual images, or ultrasound images, or can provide radiolocation data, to guide the catheter emplacement. The catheters supply a pressurized liquid including a bioactive agent, such as can be used in the treatment of cancer, for example 123I- or 125I-IUDR. The system and methods provided can be used in the treatment of locally advanced tumors, such as cancers of the brain, head or neck, esophagus, prostate, ovary, liver, pancreas, bladder or rectum.
摘要翻译：提供了一种导管系统，其适于在病人组织内的空间限定的植入物中导航，引导和植入导管或多个导管。该系统可以包括组织导航系统和探针，以通知导航系统来引导导管在目标组织内的位置。探针可以提供诸如光学视觉图像或超声图像的图像，或者可以提供无线电定位数据来引导导管放置。导管提供包括生物活性剂的加压液体，例如可用于治疗癌症，例如123I-或125I-IUDR。提供的系统和方法可用于局部晚期肿瘤的治疗，如脑，头颈部，食管，前列腺，卵巢，肝，胰腺，膀胱或直肠癌。

10. 发明申请

WO2006084141A8 SUSPENSION FORMULATION OF INTERFERON 审中-公开
标题翻译：干扰素的悬浮剂
公开(公告)号：WO2006084141A8
公开(公告)日：2006-11-09
申请号：PCT/US2006003861
申请日：2006-02-03
申请人： ALZA CORP , AYER RUPAL A , DENNIS PAULA , DESJARDIN MICHAEL A , LAM STANLEY , LIU KUI , MATSUURA JAMES E , NARAYANAN LATHA , ROHLOFF CATHERINE , ZAMORA PAULINE C
发明人： AYER RUPAL A , DENNIS PAULA , DESJARDIN MICHAEL A , LAM STANLEY , LIU KUI , MATSUURA JAMES E , NARAYANAN LATHA , ROHLOFF CATHERINE , ZAMORA PAULINE C
IPC分类号： A61K38/21 , A61K9/10 , A61K47/14 , A61K47/18 , A61K47/26 , A61K47/32 , A61P31/12
CPC分类号： A61K38/21 , A61F2250/0068 , A61K9/0004 , A61K9/0019 , A61K9/0024 , A61K9/10 , A61K9/1617 , A61K9/1623 , A61K9/1694 , A61K9/19
摘要： A suspension formulation of interferon includes a non-aqueous, single-phase vehicle including at least one polymer and at least one solvent, the vehicle exhibiting viscous fluid characteristics, and an interferon contained in a particle formulation dispersed in the vehicle. The particle formulation includes a stabilizing component comprising one or more stabilizers selected from the group consisting of carbohydrates, antioxidants, and amino acids. The suspension formulation is characterized in that less than 10% of the interferon degrades over 3 months under an accelerated storage condition.
摘要翻译：干扰素的悬浮制剂包括含有至少一种聚合物和至少一种溶剂的非水单相载体，该载体表现出粘性流体特性，以及包含在分散于载体中的颗粒制剂中的干扰素。颗粒制剂包括稳定化组分，其包含一种或多种选自碳水化合物，抗氧化剂和氨基酸的稳定剂。该悬浮液制剂的特征在于，在加速储存条件下，少于10％的干扰素在3个月内降解。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式